169 related articles for article (PubMed ID: 23942080)
1. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Bowles DW; Ma WW; Senzer N; Brahmer JR; Adjei AA; Davies M; Lazar AJ; Vo A; Peterson S; Walker L; Hausman D; Rudin CM; Jimeno A
Br J Cancer; 2013 Sep; 109(5):1085-92. PubMed ID: 23942080
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Bowles DW; Senzer N; Hausman D; Peterson S; Vo A; Walker L; Cohen RB; Jimeno A
Invest New Drugs; 2014 Dec; 32(6):1197-203. PubMed ID: 24916771
[TBL] [Abstract][Full Text] [Related]
4. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
5. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Molife LR; Fong PC; Paccagnella L; Reid AH; Shaw HM; Vidal L; Arkenau HT; Karavasilis V; Yap TA; Olmos D; Spicer J; Postel-Vinay S; Yin D; Lipton A; Demers L; Leitzel K; Gualberto A; de Bono JS
Br J Cancer; 2010 Jul; 103(3):332-9. PubMed ID: 20628389
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
10. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
Raez LE; Papadopoulos K; Ricart AD; Chiorean EG; Dipaola RS; Stein MN; Rocha Lima CM; Schlesselman JJ; Tolba K; Langmuir VK; Kroll S; Jung DT; Kurtoglu M; Rosenblatt J; Lampidis TJ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):523-30. PubMed ID: 23228990
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Locatelli MA; Aftimos P; Dees EC; LoRusso PM; Pegram MD; Awada A; Huang B; Cesari R; Jiang Y; Shaik MN; Kern KA; Curigliano G
Oncotarget; 2017 Jan; 8(2):2320-2328. PubMed ID: 27906684
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Yam C; Xu X; Davies MA; Gimotty PA; Morrissette JJD; Tetzlaff MT; Wani KM; Liu S; Deng W; Buckley M; Zhao J; Amaravadi RK; Haas NB; Kudchadkar RR; Pavlick AC; Sosman JA; Tawbi H; Walker L; Schuchter LM; Karakousis GC; Gangadhar TC
Clin Cancer Res; 2018 Jan; 24(1):22-32. PubMed ID: 29051322
[No Abstract] [Full Text] [Related]
18. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Gelmon KA; Stewart D; Chi KN; Chia S; Cripps C; Huan S; Janke S; Ayers D; Fry D; Shabbits JA; Walsh W; McIntosh L; Seymour LK
Ann Oncol; 2004 Jul; 15(7):1115-22. PubMed ID: 15205207
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P
Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]